Explore if Vivalis is the Right Wellness Supplement for You in 2025, With Full Transparency, Secure Checkout and Customer-First Support NEW YORK, August 28, 2025 (Newswire.com) - This article is for ...

Vivalis and Intercell have agreed to the terms of a merger to create a new European biotechnology company called Valneva that will specialize in vaccines and antibodies. Vivalis and Intercell have ...

Companies will collaborate on antibody discovery against multiple targets. Vaccines company Sanofi Pasteur is paying Vivalis €3 million up front for exclusive access to the latter’s Humalex® platform ...

Firm is developing VLP-based vaccines. Vivalis has granted Novavax the right to use its EB66® cell line for the production of VLP-based vaccines against several new potential viruses. The EB66 cell ...

Vivalis strengthens its management team with the appointment of Philippe Rousseau, as Chief Financial Officer VIVALIS (PARIS: VLS), a biopharmaceutical company that provides the pharmaceutical ...

VIVALIS licenses its EB66 cell line for the production of recombinant proteins to biotechnology and pharmaceutical companies. Vivalis receives up front, milestones, and royalties on its licensees' net ...

Valneva SE announces the completion of the merger of equals between Vivalis and Intercell, creating a new European biotech company focusing on vaccines and antibodies, striving to become a leader in ...

France's Vivalis is buying Austrian vaccines specialist Intercell in a deal the firms say will result in the "creation of a European biotech leader". France’s Vivalis is buying Austrian vaccines ...

PARIS, Nov 24 (Reuters) - French biotech firm Vivalis and British partner GlaxoSmithKline have won U.S. clearance to begin testing on humans for the first time flu vaccines which were produced using ...

NANTES, FRANCE--(Marketwire - June 8, 2010) - VIVALIS (NYSE Euronext: VLS) announced today the signature with Sanofi Pasteur, the vaccines division of sanofi-aventis Group (Euronext: SAN and NYSE: SNY ...

PARIS, Nov 24 (Reuters) - French biotech Vivalis and its British partner GlaxoSmithKline have won U.S. clearance to begin testing for the first time on humans flu vaccines that were produced using ...

ROUSSAY, FRANCE--(Marketwire -08/21/12)- Successful growth of BioDiem's Virus in VIVALIS EB66(®) Cell Line Highlights: * BioDiem confirms successful and abundant growth of its virus in VIVALIS' ...